Omnicell (OMCL) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving Omnicell (OMCL) right now is Shift toward recurring software and services: Omnicell is steering its revenue mix away from one-time hardware sales toward recurring subscription, cloud, and Advanced Services revenue, which it tracks through annual recurring revenue (ARR). Revenue (FY2025) is ~$1.185 billion (up ~7%). If that keeps playing out, the setup is favourable; the risk to it is omnicell's product revenue depends heavily on hospital and health-system capital budgets, which are cyclical and can be cut quickly when providers face financial pressure, making bookings and revenue lumpy. No one can predict where OMCL trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Omnicell (OMCL) higher?
1. Shift toward recurring software and services.
Omnicell is steering its revenue mix away from one-time hardware sales toward recurring subscription, cloud, and Advanced Services revenue, which it tracks through annual recurring revenue (ARR). Recurring revenue tends to be higher-margin and more predictable than lumpy capital-equipment sales. Continued growth in ARR and the attach rate of software to installed cabinets is central to the company's margin-expansion story.
2. Large installed base and replacement cycle.
Omnicell has a deep footprint of automated dispensing cabinets and pharmacy systems across US hospitals and health systems, which creates recurring service revenue and upgrade or replacement opportunities as older equipment ages. That installed base is a switching-cost moat because ripping out medication-management infrastructure is disruptive for a hospital. New product cycles and expansion into outpatient, retail, and specialty pharmacy settings widen the addressable market.
3. Recovering hospital capital spending and bookings.
After a slump in hospital capital budgets following the pandemic boom, Omnicell has pointed to stabilizing and recovering product bookings, which are a leading indicator of future revenue. First-quarter 2026 revenue grew about 15% year over year to roughly $310 million, and the company raised its full-year non-GAAP EPS guidance. A sustained recovery in health-system capital spending would support both the hardware and the attached-software businesses.
4. Margin and profitability improvement.
Management has focused on cost discipline and mix shift to lift profitability, with non-GAAP EBITDA of about $140 million in 2025 and a step-up in early 2026 (Q1 2026 non-GAAP EPS of about $0.55 versus about $0.26 a year earlier). The 2026 guidance implied a meaningful increase in non-GAAP EPS toward the roughly $1.80 to $2.00 range. Whether these gains translate into durable GAAP earnings is a key watch item.
What could weigh on OMCL?
Omnicell's product revenue depends heavily on hospital and health-system capital budgets, which are cyclical and can be cut quickly when providers face financial pressure, making bookings and revenue lumpy. It competes against larger and better-capitalized rivals, most notably BD (Becton Dickinson) with its Pyxis dispensing line, along with Baxter, Swisslog, and other automation vendors, which can pressure pricing and market share. The company's GAAP profitability has at times been thin relative to its share price, so a large gap between GAAP and non-GAAP earnings and a high trailing P/E leave little room for execution missteps. Long installation and implementation cycles, customer concentration among big health systems, and integration risk from acquisitions add operational uncertainty. Broader healthcare-policy shifts, reimbursement pressure, supply-chain costs, and any product-reliability or regulatory issues around medication safety could also weigh on results.
Where OMCL trades today
A forecast starts from where the stock actually is. These are OMCL's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for OMCL as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a OMCL forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the OMCL guide and whether OMCL is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the OMCL outlook
The bottom line: what is driving Omnicell (OMCL) is Shift toward recurring software and services, with revenue (fy2025) at ~$1.185 billion (up ~7%). If that keeps playing out the setup is favourable; the risk is omnicell's product revenue depends heavily on hospital and health-system capital budgets, which are cyclical and can be cut quickly when providers face financial pressure, making bookings and revenue lumpy. No one can predict the price, so treat any OMCL forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around OMCL with Walnut
Use Omnicell as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Omnicell (OMCL)?
+
No one can reliably predict where OMCL will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Omnicell higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive OMCL higher?
+
The main growth drivers are Shift toward recurring software and services; Large installed base and replacement cycle; Recovering hospital capital spending and bookings. Whether they play out is the real question, not a guaranteed path.
What are the risks to OMCL?
+
Omnicell's product revenue depends heavily on hospital and health-system capital budgets, which are cyclical and can be cut quickly when providers face financial pressure, making bookings and revenue lumpy. It competes against larger and better-capitalized rivals, most notably BD (Becton Dickinson) with its Pyxis dispensing line, along with Baxter, Swisslog, and other automation vendors, which can pressure pricing and market share. The company's GAAP profitability has at times been thin relative to its share price, so a large gap between GAAP and non-GAAP earnings and a high trailing P/E leave little room for execution missteps. Long installation and implementation cycles, customer concentration among big health systems, and integration risk from acquisitions add operational uncertainty. Broader healthcare-policy shifts, reimbursement pressure, supply-chain costs, and any product-reliability or regulatory issues around medication safety could also weigh on results.
Will OMCL stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Omnicell's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is OMCL a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the OMCL "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.